HALISTER: Bristol-Myers Cuts 2017 Adj. EPS Forecast; 4Q Opdivo Rev. Beats

Bristol-Myers Cuts 2017 Adj. EPS Forecast; 4Q Opdivo Rev. Beats

(Bloomberg) -- Bristol-Myers Squibb cuts 2017 adj. EPS view to $2.70-$2.90, saw $2.85-$3.05 on Oct. 27, est. $2.86.
  • Sees 2017 global rev. increasing in low-single digits
  • Sees 2017 gross margin 72%-73%, est. 73.9%
  • 4Q adj. EPS 63c, est. 67c (range 61c-71c)
  • 4Q rev. $5.24b, est. $5.12b (range $4.97b-$5.31b)
    • Opdivo $1.31b, est. $1.17b
    • Eliquis $948m, est. $967.2m
    • Orencia $625m, est. $607.5m
    • Sprycel $494m, est. $473.6m
    • Yervoy $264m, est. $299.9m
    • Hepatitis C franchise $226m, est. $256.8m
    • Empliciti $47m, est. $51.8m
  • BMY says forecast assumes no generic Sprycel competition in Europe following appeal of patent office decision
  • Conf. call 10:30am 877-201-0168, pw 60705823 or listen to it on LIVE
  • NOTE: Analysts focused on Opdivo after setback in lung cancer; see preview
Statement link
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
BMY US (Bristol-Myers Squibb Co)
4528 JP (Ono Pharmaceutical Co Ltd)
4578 JP (Otsuka Holdings Co Ltd)

To de-activate this alert, click here

UUID: 7947283